‘Patent opposition’ seeks to ensure millions of people left out of Gilead licensing deals can access affordable generics
26 February 2016
Friday, February 26, 2016
Access: Patent challenge hearing on Gilead hepatitis C drug sofosbuvir starts in India
Access: Patent challenge hearing on Gilead hepatitis C drug sofosbuvir starts in India
‘Patent opposition’ seeks to ensure millions of people left out of Gilead licensing deals can access affordable generics
26 February 2016
New Delhi/New York – In proceedings that could have major implications for millions of people waiting for affordable access to a life-saving hepatitis C drug, the Indian Patent office this week will begin hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges US$1,000 per pill in the US.
‘Patent opposition’ seeks to ensure millions of people left out of Gilead licensing deals can access affordable generics
26 February 2016
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment